-
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and licensing agreement with US-based EQRx Inc. (NASDAQ: EQRX) concerning the epidermal growth factor receptor (EGFR) inhibitor Ameile (almonertinib). As a result, the Chinese company will regain research and development (R&D), manufacturing, and commercialization rights to…
-
EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction
•
US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for the company to be fully acquired by US-based Revolution Medicines (NASDAQ: RVMD). The transaction will be executed as an all-stock deal, with Revolution issuing shares to EQRx shareholders, anticipating the acquisition of over USD 1…
-
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
•
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a significant shift in strategy. The company, which aimed to disrupt high drug prices in the US market with cheaply sourced innovative drugs, has decided to abandon these plans. Consequently, EQRx will terminate the development of…
